uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's DiseaseGlobeNewsWire • 06/23/22
CORRECTION -- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 06/22/22
Mizuho Comments On UniQure's Upcoming Low-Dose Huntington's Gene Therapy Trial DataBenzinga • 06/13/22
uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority ReviewGlobeNewsWire • 05/24/22
FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority ReviewPRNewsWire • 05/24/22
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual MeetingGlobeNewsWire • 05/02/22
uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 05/02/22
European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia BPRNewsWire • 03/28/22
uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's DiseaseGlobeNewsWire • 03/21/22
uniQure Announces 2021 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 02/25/22
uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's DiseaseGlobeNewsWire • 02/07/22
After Plunging 33.5% in 4 Weeks, Here's Why the Trend Might Reverse for uniQure (QURE)Zacks Investment Research • 01/06/22
UniQure Shares Fall After Clinical Update From Huntington's Disease Gene Therapy TrialBenzinga • 12/16/21
uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's DiseaseGlobeNewsWire • 12/16/21
uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia BGlobeNewsWire • 12/09/21